Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials

被引：0

作者：

Qu, Xiaoyu ^{[1
,2
]}

Othus, Megan ^{[1
,3
]}

Davison, Jerry ^{[1
]}

Yan, Liying ^{[4
]}

Estey, Elihu H. ^{[2
,5
,6
]}

Radich, Jerry ^{[1
,2
,3
,7
]}

Erba, Harry P. ^{[3
,8
]}

Appelbaum, Frederick R. ^{[1
,2
,3
,7
]}

Fang, Min ^{[1
,2
,3
,7
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[2] Seattle Canc Care Alliance, Seattle, WA USA

[3] SWOG Leukemia Comm, Portland, OR USA

[4] EpigenDx Inc, Boston, MA USA

[5] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA

[6] Univ Washington, Div Hematol, Seattle, WA 98195 USA

[7] Univ Washington, Seattle, WA 98195 USA

[8] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[41] High Expression of Lymphoid Enhancer-Binding Factor 1 (LEF1) Is a Novel, Favorable Prognostic Marker in Cytogenetically Normal AML and Is Associated with Upregulation of T-Lymphoid Lineage Markers in AML Blasts
Metzeler, Klaus H.
Heilmeier, Bernhard
Petropoulos, Konstantin
Sauerland, Maria C.
Heinecke, Achim
Berdel, Wolfgang E.
Buechner, Thomas
Braess, Jan
Spiekermann, Karsten
Feuring-Buske, Michaela
Hiddemann, Wolfgang
Bohlander, Stefan K.
Buske, Christian
BLOOD, 2009, 114 (22) : 165 - 165
[42] PROGNOSTIC SIGNIFICANCE OF MOLECULAR MARKERS IN NORMAL KARYOTYPE-AML: A SINGEL CENTER EXPERIENCE
Spinelli, O.
Tosi, M.
Guerini, V.
Zanghi, P.
Franchi, M.
Taboni, I.
Magri, M.
Zanotti, C.
Intermesoli, T.
Oldani, E.
Bassan, R.
Rambaldi, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 206 - 206
[43] Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML
Hollink, I. H. I. M.
Zwaan, C. M.
Zimmermann, M.
Arentsen-Peters, T. C. J. M.
Pieters, R.
Cloos, J.
Kaspers, G. J. L.
de Graaf, S. S. N.
Harbott, J.
Creutzig, U.
Reinhardt, D.
van den Heuvel-Eibrink, M. M.
Thiede, C.
LEUKEMIA, 2009, 23 (02) : 262 - 270
[44] Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML
I H I M Hollink
C M Zwaan
M Zimmermann
T C J M Arentsen-Peters
R Pieters
J Cloos
G J L Kaspers
S S N de Graaf
J Harbott
U Creutzig
D Reinhardt
M M van den Heuvel-Eibrink
C Thiede
Leukemia, 2009, 23 : 262 - 270
[45] DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients treated on clinical trials
Tran, Q.
Upadhyaya, S.
Billups, C.
Onar-Thomas, A.
Carey, S.
Alom, M.
Robinson, G.
Ellison, D.
Gajjar, A.
Orr, B.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2023, 82 (06): : 544 - 544
[46] CEBPA Methylation as a Prognostic Biomarker in Adult Patients with De Novo AML.
Chen, Hsin-Yu
Lin, Tsung-Chin
Chou, Wen-Chien
Hou, Hsin-An
Tien, Hwei-Fang
Lin, Liang-In
BLOOD, 2009, 114 (22) : 628 - 628
[47] Identification of Survival-Related Genes in Acute Myeloid Leukemia (AML) Based on Cytogenetically Normal AML Samples Using Weighted Gene Coexpression Network Analysis
Chen, Tingting
Zhang, Juan
Wang, Yinying
Zhou, Hebing
DISEASE MARKERS, 2022, 2022
[48] Influence of FLT3-ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients
Jiang, Xuejie
Yin, Changxin
Sun, Junya
Cheng, Jiaying
Wang, Qiang
Yu, Guopan
Jiang, Ling
Xu, Dan
Liu, Xiaoli
Feng, Ru
Liu, Qifa
BLOOD, 2018, 132
[49] MARKERS PROGNOSTIC FOR SURVIVAL IN ZIDOVUDINE TREATED, HIV-INFECTED CHILDREN
MCKINNEY, RE
PEDIATRIC RESEARCH, 1994, 35 (04) : A187 - A187
[50] PROGNOSTIC MARKERS AND SURVIVAL IN A CONTEMPORARY SERIES OF GLIOBLASTOMAS TREATED AT A SINGLE CENTRE
Moiyadi, Aliasgar
Kannan, Sadhana
Sridhar, Epari
Gupta, Tejpal
Shetty, Prakash
Jalali, Rakesh
NEURO-ONCOLOGY, 2013, 15 : 121 - 121

← 1 2 3 4 5 →